The US is the bigger Cancer Supportive Care Drugs market: $10.4 Bn against $451 Mn in 2023, about 23 times as large.
India grows faster: 7.7% a year, against 2.7%. The gap still grows from $10 Bn to $12.6 Bn by 2033.
Clinical research: 1,720 active trials in the US, 33 in India.
| Measure |  US |  India |
|---|---|---|
| Market size, 2023 | $10.4 Bn | $451 Mn |
| Market size, 2033 projected | $13.6 Bn | $947 Mn |
| Growth a year (CAGR) | 2.7% | 7.7% |
| Money added, 2023–2033 | $3.2 Bn | $496 Mn |
| Share of the world market | 42% | 1.8% |
| Size rank of 24 countries | #1 | #12 |
| Market per person, 2023 | $30 | $0.31 |
| Active clinical trials | 1,720 | 33 |
| Full report | US report | India report |
Year by year, 2023 to 2033
US India · values between 2023 and 2033 are projected from the 2023 size and the CAGR.
Quick answers
Which is bigger in Cancer Supportive Care Drugs, US or India?
The US is the bigger Cancer Supportive Care Drugs market: $10.4 Bn against $451 Mn in 2023, about 23 times as large.
Which grows faster in Cancer Supportive Care Drugs, US or India?
India grows faster: 7.7% a year, against 2.7%. The gap still grows from $10 Bn to $12.6 Bn by 2033.
More Cancer Supportive Care Drugs comparisons
Sources: market size and growth: Acuitas Health Analytics research (2023 base year, forecasts to 2033). Trials: ClinicalTrials.gov (fetched 10 Nov 2026); found by search words, so counts are a guide. Population: World Bank.